Frontlight ResearchEarly access
Thalassaemia trials in Canada
6 of 7 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 4Enrolling by invitationA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Hamilton, Toronto
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - Phase 3CompletedA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Montreal, Toronto, Vancouver
- Age
- 2 years and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - Phase 3Enrolling by invitationA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- Toronto, Vancouver
- Age
- 2 years to 64 years
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Toronto
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 1/2Enrolling by invitationThe BENeFiTS Trial in Beta Thalassemia Intermedia
- Where
- Toronto
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Phoenicia BioScience
See details and how to joinNCT04432623 - Phase 1/2Taking peopleThal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
- Where
- Toronto
- Age
- 1 year to 18 years
- People
- 20
- Run by
- The Hospital for Sick Children
See details and how to joinNCT05426252